

PURPOSE OF BILL: HB 1055

To establish coverage diagnosis and treatment to slow the progression of Alzheimer's disease or other dementia-related disease under the State and Public School Life and Health Insurance Program.

ACTUARIAL STATEMENT

The Fiscal Impact Statement was prepared according to generally accepted actuarial principles and practices, in compliance with ACT 112. The Statement provides an estimate of the financial and actuarial effect of the proposed change(s) on the Plans, if possible. The Statement makes no comment or opinion with regard to the merits of the measure for which the Statement is prepared; however, any identified technical or mechanical defects have been noted.

We have reviewed the input and results of our analysis for reasonableness and relied upon the data and information provided by the Plans and their Claims Processing Contractors.

A handwritten signature in black ink, appearing to read "Patrick Klein".

3/12/2025

Patrick Klein, FSA, MAAA
Vice President, Segal

Date

A handwritten signature in black ink, appearing to read "Matthew Kersting".

3/12/2025

Matthew Kersting, FSA, MAAA
Vice President, Segal

Date

PROJECTED COSTS

Plan	Plan Design Change	Estimated Cost/(Savings)
EBD	No Change	Negligible Impact

PRICING APPROACH AND COMMENTS

House Bill 1055 requires the State health plan to cover diagnosis and treatment to slow the progression of Alzheimer's disease or other dementia-related disease.

The EBD Plan currently covers services related to diagnostic testing, and care planning for members with Alzheimer's disease and other types of dementia. The plan also covers the 4 oral medications used for Alzheimer's dementia. None of these products are subject to prior authorization or step therapy.

There may be treatment options not currently covered by the plan, but given a small number of members affected by Alzheimer's disease on the data (0.11 members per 1,000), any additional costs would be considered negligible.